In this white paper, we draw lessons from industries as diverse as food products and toy manufacturing to illustrate how pharmaceutical companies can effectively access innovation outside the traditional in-house R&D model. To read more, click the PDF link below. A version of this article was also published in IN VIVO here.
Life sciences considerations for investment treaty disputes
Greg Bell, Andrew Tepperman, and Justin Ho co-authored a chapter in the ninth edition of The Investment Treaty Arbitration Review. The chapter titled...